Cardiokol

Company Overview

Snapshot

Founded in August 2017 by Alon Goren, Eli Attar, and Pini Sabach, Cardiokol operates with 1–10 employees. The company has raised $8 million across two funding rounds.

Business overview

Cardiokol is a digital telehealth company specializing in the development of voice-based markers and methods for monitoring and screening heart rhythm disorders. The company's core technology leverages proprietary AI and machine learning algorithms implemented across various speech platforms, including landlines, smartphones, smart speakers, and voice assistants. Cardiokol provides low-cost, long-term, and user-friendly monitoring solutions primarily targeting at-risk populations of older adults (65+) in the Digital Healthcare and Patient Remote Monitoring sectors, serving markets such as the United States and Europe.

Strategic signal

In July 2026, Cardiokol, an AI startup focused on stroke detection technology, sought court protection. This development signals a significant operational challenge for the company, indicating potential financial restructuring or strategic re-evaluation, which could impact its trajectory in the digital health market.

Company Intelligence Q&A

What is Cardiokol's primary focus?

Cardiokol develops voice-based markers and methods for large-scale monitoring and screening of heart rhythm disorders, utilizing proprietary technology implemented in speech platforms.

When was Cardiokol founded and by whom?

Cardiokol was founded in August 2017 by Alon Goren, Eli Attar, and Pini Sabach.

What was a significant recent development for Cardiokol?

In July 2026, Cardiokol, an AI startup developing stroke detection technology, sought court protection.

Which program did Cardiokol join in November 2021?

In November 2021, Cardiokol joined Bayer's G4A program, which supports digital health pioneers.